Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
NCT06389877Phase 2Recruiting
- Sponsor
- Beam Therapeutics
- Start
- Jun 2024
- Primary completion
- May 2028
- Modality
- CRISPR-Cas9, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 6
01
Overview
A Phase 2 trial of BEAM-302 in alpha-1 antitrypsin deficiency (AATD), sponsored by Beam Therapeutics. Started Jun 2024; status: recruiting.
02
Drugs
BEAM-302
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT06389877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06389877.